Inicia sesión Registrate Mi Biblioteca biblioteca abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de artículos sobre la enfermedad de Alzheimer/demencias y sobre los Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.

173896 ARTíCULOS , VIENDO DEL 172861 AL 172875

PUBMED

Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?

Pintér D, Forjaz MJ, Martinez-Martin P, Rodriguez-Blazquez C, Ayala A, Juhász A, Harmat M, Janszky J, Kovács N.

J Parkinsons Dis. 2020;10(1):275-282. doi: 10.3233/JPD-191800.

0

0

0

PUBMED

High density microelectrode recording predicts span of therapeutic tissue activation volumes in subthalamic deep brain stimulation for Parkinson disease

Lu CW, Malaga KA, Chou KL, Chestek CA, Patil PG.

Brain Stimul. 2020 Mar-Apr;13(2):412-419. doi: 10.1016/j.brs.2019.11.013. Epub 2019 Dec 4.

0

0

0

PUBMED

Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database

de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL.

Parkinsonism Relat Disord. 2020 Jan;70:55-59. doi: 10.1016/j.parkreldis.2019.12.011. Epub 2019 Dec 17.

0

0

0

PUBMED

Association of periodic limb movements during sleep and Parkinson disease: A retrospective clinical study.

Hwang SR, Hwang SW, Chen JC, Hwang JH.

Medicine (Baltimore). 2019 Dec;98(51):e18444. doi: 10.1097/MD.0000000000018444.

0

0

0

PUBMED

MicroRNAs - diagnostic markers in Parkinson disease?

Fyfe I.

Nat Rev Neurol. 2020 Feb;16(2):65. doi: 10.1038/s41582-019-0305-y.

0

0

0

PUBMED

Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease

Campbell MC, Jackson JJ, Koller JM, Snyder AZ, Kotzbauer PT, Perlmutter JS.

Neurology. 2020 Feb 18;94(7):e718-e728. doi: 10.1212/WNL.0000000000008677. Epub 2019 Dec 18.

0

0

0

PUBMED

Translation, Cultural Adaptation, and Validation of the Hiligaynon Montreal Cognitive Assessment Tool (MoCA-Hil) Among Patients With X-Linked Dystonia Parkinsonism (XDP).

Aliling NB, Rivera AS, Jamora RDG.

Front Neurol. 2019 Nov 28;10:1249. doi: 10.3389/fneur.2019.01249. eCollection 2019.

0

0

0

PUBMED

Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease

Quarracino C, Otero-Losada M, Capani F, Pérez-Lloret S.

Clin Auton Res. 2020 Jun;30(3):265-271. doi: 10.1007/s10286-019-00652-6. Epub 2019 Dec 17.

0

0

0

PUBMED

Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease

Maiti B, Koller JM, Snyder AZ, Tanenbaum AB, Norris SA, Campbell MC, Perlmutter JS.

Neurology. 2020 Jan 28;94(4):e384-e396. doi: 10.1212/WNL.0000000000008754. Epub 2019 Dec 17.

0

0

0

PUBMED

Overlapping genetic architecture between Parkinson disease and melanoma

Dube U, Ibanez L, Budde JP, Benitez BA, Davis AA, Harari O, Iles MM, Law MH, Brown KM; 23andMe Research Team; Melanoma-Meta-analysis Consortium, Cruchaga C.

Acta Neuropathol. 2020 Feb;139(2):347-364. doi: 10.1007/s00401-019-02110-z. Epub 2019 Dec 16.

0

0

0

PUBMED

Cellular alterations identified in pluripotent stem cell-derived midbrain spheroids generated from a female patient with progressive external ophthalmoplegia and parkinsonism who carries a novel variation (p.Q811R) in the POLG1 gene.

Chumarina M, Russ K, Azevedo C, Heuer A, Pihl M, Collin A, Frostner EÅ, Elmer E, Hyttel P, Cappelletti G, Zini M, Goldwurm S, Roybon L.

Acta Neuropathol Commun. 2019 Dec 16;7(1):208. doi: 10.1186/s40478-019-0863-7.

0

0

0

PUBMED

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.

Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C.

JAMA Neurol. 2019 Dec 16. doi: 10.1001/jamaneurol.2019.4200. [Epub ahead of print]

0

0

0

PUBMED

The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease.

Espay AJ, Hauser RA, Armstrong MJ.

JAMA Neurol. 2019 Dec 16. doi: 10.1001/jamaneurol.2019.3983. [Epub ahead of print] No abstract available.

0

0

0

PUBMED

Modulation of Nigrofugal and Pallidofugal Pathways in Deep Brain Stimulation for Parkinson Disease

Avecillas-Chasin JM, Honey CR.

Neurosurgery. 2020 Apr 1;86(4):E387-E397. doi: 10.1093/neuros/nyz544.

0

0

0

PUBMED

How Important Is the Use of Cocaine and Amphetamines in the Development of Parkinson Disease? A Computational Study

Pregeljc D, Teodorescu-Perijoc D, Vianello R, Umek N, Mavri J.

Neurotox Res. 2020 Mar;37(3):724-731. doi: 10.1007/s12640-019-00149-0. Epub 2019 Dec 11.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neuroacademy